Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension

S. Minder, M. Fischler, B. Muellhaupt, M.P. Zalunardo, R. Jenni, P-A. Clavien, R. Speich
European Respiratory Journal 2004 24: 703-707; DOI: 10.1183/09031936.04.00133203
S. Minder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Fischler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Muellhaupt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.P. Zalunardo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Jenni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P-A. Clavien
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Speich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Portopulmonary hypertension (PPHTN) is associated with poor prognosis and high perioperative mortality after orthotopic liver transplantation.

This study documents the first case of a patient with PPHTN who was successfully bridged to orthotopic liver transplantation with i.v. iloprost, a stable prostacyclin analogue. The PPHTN had resolved completely 4 months after successful transplantation.

In conclusion, portopulmonary hypertension is a relative contraindication to orthotopic liver transplantation, which should be attempted only if pulmonary haemodynamics improve with prostanoids. In this context, iloprost may be a valuable alternative to epoprostenol.

  • Epoprostenol
  • iloprost
  • liver cirrhosis
  • liver transplantation
  • portopulmonary hypertension
  • pulmonary hypertension

Two distinct pulmonary circulatory syndromes have been described in association with advanced liver disease: 1) hepatopulmonary syndrome, and 2) portopulmonary hypertension (PPHTN) 1–3. Hepatopulmonary syndrome is characterised by hypoxaemia caused by pulmonary vascular dilatations and direct arteriovenous shunts (table 1⇓). Most centres consider the syndrome to be an indication for orthotopic liver transplantation (OLT) 2. Complete resolution of the syndrome is well documented 4. PPHTN is a specific condition characterised by an elevated mean pulmonary arterial pressure (Ppa), increased pulmonary vascular resistance (PVR), and a normal pulmonary artery occlusion pressure (PAOP) in the presence of portal hypertension and absence of other potential causes of pulmonary hypertension, such as chronic thromboembolic disease, valvular disease, collagen vascular disease, HIV infection, and ingestion of certain toxins or appetite suppressants. In the World Health Organization (WHO) classification, PPHTN represents a subset of pulmonary arterial hypertension 5. There are only a few case reports of patients with the coexistence of PPHTN and hepatopulmonary syndrome 1. Right-to-left intracardiac shunts through a patent foramen ovale, as a cause of hypoxaemia, should be excluded in this situation.

View this table:
  • View inline
  • View popup
Table 1—

Definition of portopulmonary hypertension (PPHTN) and hepatopulmonary syndrome

PPHTN is a well-recognised complication of advanced liver disease, and affects 2–5% of such patients. However, in liver transplant candidates, the prevalence is higher and ranges 4–26%. Many of these patients exhibit high-flow states (normal or low PVR) or increased central blood volume (increased PAOP). Thus, the incidence of true PPHTN (increased PVR) is ∼4–9% 6–8. Prognosis is poor, with a mean survival of 15 months after diagnosis 9. Perioperative mortality in patients who undergo OLT is extremely high, andseems to correlate with the degree of increase in Ppa. Although patients with mild-to-moderate PPHTN (Ppa 25–35 mmHg) can safely undergo transplantation without increased risk 6–8, 10, in patients with a Ppa of 35–49 mmHg, the perioperative mortality rate is ∼50%, and reaches 70–100% in those with a Ppa of >50 mmHg 10. The high perioperative mortality results primarily from right ventricular dysfunction. Thus, severe PPHTN has been considered to be a contraindication to OLT. Nevertheless, thereduction in Ppa and PVR, as well as the improvement in right ventricular function during continuous infusion of epoprostenol, may facilitate successful OLT 11–15. The disadvantage of epoprostenol is its very short half-life and the rapid development of tolerance, necessitating increasing doses of the drug to achieve the same effects. Thus, the more stable prostacyclin analogue iloprost might be an alternative treatment option.

Case report

In August 1996, a 48-yr-old patient underwent laparotomy for a perforated gastric ulcer. Routine laboratory examinations revealed elevated liver enzyme levels and liver cirrhosis as a result of chronic hepatitis C, and chronic alcohol abuse was subsequently diagnosed. After a second episode of variceal bleeding in January 1998, the patient successfully stopped drinking alcohol. The clinical course was complicated by several episodes of ascites and jaundice, and, in December 1999, the patient was evaluated for OLT. At that time, no contraindications were found. Echocardiography revealed a normal rightventricular systolic pressure (RVSP; 27 mmHg), measured over right atrial pressure, and the patient was listed for transplantation. In September 2000, a routine control examination revealed a multifocal hepatocellular carcinoma with three nodules, located in segments IV and VIII. Three transarterial segmental hepatic chemoembolisations were performed between September 2000 and July 2001, and they resulted in partial tumour remission.

In January 2001, the patient was admitted for transplantation when a donor organ became available. Induction of anaesthesia was unremarkable, except for right heart catheterisation, which revealed severe pulmonary hypertension with a Ppa of 50 mmHg. In view of this unexpected major risk factor, the transplantation was cancelled. Further diagnostic work-up excluded diseases of the respiratory system, thromboembolism, heart failure and valvular heart diseases. The alveolar–arterial oxygen tension gradient was 16 mmHg (normal <20 mmHg). Thus, severe PPHTN was diagnosed. Not even retrospectively, reviewing the video sequence of the first echocardiographic examination in December 1999, were there any signs of elevated pulmonary arterial pressure, and the examination performed at the same time showed an RVSP of 74 mmHg and the distinctive pattern of severe pulmonary hypertension.

The patient complained only of slight dyspnoea on exertion (WHO functional class II). Analogous to the protocol of Kuo et al. 16, invasive haemodynamic testing was performed (table 2⇓), and continuous i.v. therapy with iloprost started at a gradually increasing infusion rate of ≤200 µg·day−1 (1.8 ng·kg body weight−1·min−1). Iloprost was chosen since it is routinely used instead of epoprostenol in the present authors' pulmonary hypertension programme, primarily because of its longer half-life, its possible lesser tendency to tolerance development, and the need for lower doses and, therefore, lower costs. After 3 months of iloprost infusion, the patient's 6-min walking distance improved, and a significant reduction in RVSP to <40 mmHg could be achieved.

View this table:
  • View inline
  • View popup
Table 2—

Haemodynamic and echocardiographic profile throughout the patient's course, before and after orthotopic liver transplantation (OLT)

In August 2001, the patient underwent OLT. The intraoperative course was uneventful. Iloprost was continued throughout the transplant procedure. Cardiac function, monitored by electrocardiography and right heart catheterisation, remained stable and without exacerbation of pulmonary hypertension after reperfusion of the transplanted liver. Low-dose noradrenalin was given for 24 h to stabilise the systemic blood pressure. Immunosuppressive therapy with tacrolimus was commenced. After reconstitution of liver function, the iloprost dose had to be increased to 300 µg·day−1 (2.7 ng·kg body weight−1·min−1) because of an increase in Ppa to 45 mmHg.

Postoperative recovery was favourable and without any major complications. The patient was extubated on postoperative day 1, transferred to the ward on day 3, and discharged from hospital on day 13. Treatment with iloprost was continued. The explanted cirrhotic liver showed a moderately differentiated hepatocellular carcinoma in the left lobe and two circumscribed completely necrotic areas in the right lobe, as well as signs of chronic hepatitis with minimal inflammatory activity. In December 2001, 4 months after liver transplantation, all echocardiographic signs of pulmonary hypertension had disappeared, and the RVSP was 27 mmHg. The patient was completely asymptomatic, and the continuous i.v. therapy with iloprost was stopped. The patient is still doing well 25 months after OLT. Echocardiographic results remain normal. Meanwhile, reinfection with hepatitis C virus has been documented and treatment with pegylated interferon alpha-2a and ribavirin has begun. There are no signs of tumour recurrence.

Discussion

The first patient with severe PPHTN successfully bridged to OLT with continuous i.v. iloprost, a stable prostacyclin analogue, is presented. Pulmonary hypertension resolved 4months after successful transplantation and, subsequently, vasodilator therapy could be stopped. The patient's clinical course >2 yrs after OLT is excellent, and there is no recurrence of pulmonary hypertension.

Until the mid-1990s, severe PPHTN was considered to beanabsolute contraindication to OLT. When the Ppa is >50 mmHg, perioperative mortality is 70–100% 10. In 1997, after encouraging results from the continuous administration of epoprostenol in idiopathic pulmonary arterial hypertension 17, Kuo et al. 18 demonstrated a favourable haemodynamic effect of this treatment in four cases of PPHTN, with a 22–71% decrease in PVR. One year later, the same group reported the first case undergoing successful OLT after 4 months of preoperative treatment with i.v. epoprostenol 11. The patient was taken off epoprostenol 3 months aftertransplantation with near normal pulmonary haemodynamics.

To date, only four other cases who bridged to OLT with continuous i.v. epoprostenol have been described (table 3⇓) 12–15. Although one patient died due to right heart failure 28 days after OLT, the other three are alive and successfully weaned from vasodilator therapy.

View this table:
  • View inline
  • View popup
Table 3—

Pulmonary haemodynamics and outcomes of patients with portopulmonary hypertension treated with prostaglandins prior to orthotopic liver transplantation (OLT)

The novel aspect of the present case is the treatment with continuous infusion of iloprost instead of epoprostenol. Iloprost is a prostacyclin analogue that has several advantages over epoprostenol. Whereas the latter has to be protected from light and needs to be dissolved in a glycine buffer for i.v. administration, iloprost is much more chemically stable. Moreover, iloprost has a biphasic disposition, with longer half-lives of 3–4 and 30 min, in contrast to the half-life of <5 min of epoprostenol 19. In addition, much lower doses of iloprost are needed for a comparable haemodynamic effect 20.

A recent case series has cast doubt on the efficacy of epoprostenol, since six of the 10 patients died after a mean follow-up time of 9 months, at least two of them possibly due to PPHTN after 5 and 6 months, respectively 12. The same group recently reported a peculiar syndrome of progressive splenomegaly with worsening thrombocytopenia and leukopenia in four patients on continuous i.v. epoprostenol 21. One of them died as a result of sepsis following splenic embolisation and subsequent splenectomy. Thus, the present finding that iloprost has a comparable effect to that of epoprostenol suggests that iloprost might become a valuable treatment alternative in severe PPHTN.

The excessive perioperative mortality in patients with severe PPHTN undergoing OLT suggests that early diagnosis is crucial. Since, as in the present case, patients with even severe PPHTN are not infrequently asymptomatic 10, 22, 23, and PPHTN is a serious but treatable disorder, screening for pulmonary hypertension plays a key role in the management of OLT candidates. For the detection of pulmonary hypertension, ECG and plain chest radiography are unreliable, as their sensitivity is only ∼60% and ∼80%, respectively 23. Transthoracic echocardiography is a sensitive noninvasive diagnostic method. It is considered the screening modality of choice for all forms of pulmonary hypertension, including PPHTN. In a study of 165 OLT candidates 24, thesensitivity and specificity of RVSP at a relatively low cut-off of >30 mmHg (including a right atrial pressure of 5 mmHg), with respect to a Ppa of >25 mmHg, were 100 and96%, respectively. However, half of these patients with invasively confirmed PPHTN had a Ppa of <40 mmHg and could thus undergo OLT without additional treatment. In another study of 74OLT candidates using a higher RVSP cut-off of ≥50 mmHg, sensitivity and specificity were 97 and 72%, respectively 25. Only one patient with an RVSP of<50 mmHg had a Ppa of ≥35 mmHg, but the invasively determined systolic pulmonary arterial pressure was only 55 mmHg. Thus, Doppler echocardiography is an accurate screening test, and all OLT candidates with an RVSP of ≥50 mmHg should undergo right heart catheterisation. Although rare, PPHTN can develop after evaluation for OLT, as was the case in the present patient. In their large series, Colle et al. 24 describe three patients who developed PPHTN within only 3–5 months after the initial evaluation for OLT. In their retrospective review of 43 patients, Krowka et al. 10 found that, in 65%, PPHTN was diagnosed in the operating room immediately prior to OLT. Thus, regular echocardiographic examinations of OLT candidates on the waiting list are necessary, although the optimal screening frequency remains to be determined. Inaccordance with the Mayo Clinic Liver Transplantation Program (M.J. Krowka, Division of Pulmonary and Critical Care, The Mayo Clinic, Rochester, MN, USA, personal communication), the patients on the current authors' waiting list are screened every 12 months if the first echocardiography is normal,and every 6 months if the RVSP is 35–50 mmHg. Patients with an RVSP of >50 mmHg undergo right heart catheterisation and initiation of vasodilator therapy, with theaim of decreasing Ppa to <35–40 mmHg and PVR to<400 dyn·s·cm−5 with good cardiac output before listing them for OLT.

Since the aetiology of PPHTN is unknown 26, it is difficult to predict whether pulmonary hypertension will resolve after OLT. Literature data indicate that, as in the present case, almost all patients with PPHTN show improved or normalised pulmonary artery pressures within 6 months after OLT 27–30, but this may take up to 2 yrs 31. In literature reviews, it was found that 19 out of 25 (76%) patients ever transplanted for PPHTN showed improved or resolved pulmonary hypertension 6, 8, 10. In individual cases, persistence 6, 14, 32, 33, progression 6, 34, recurrence 35 or even de novo evolution 36 of pulmonary hypertension after OLT have been observed. A comparison of the preoperative haemodynamics revealed that patients who showed improved or resolved pulmonary hypertension had a lower Ppa (43 mmHg; 95% confidence interval (CI) 39–47 mmHg) compared with those who did not (51 mmHg; 95% CI 42–61 mmHg). This difference, however, was not significant (p=0.1). Thus, owing to the large overlap between the two groups, the individual postoperative course cannot be predicted from the severity of PPHTN. It is noteworthy that the present case represents the one with the highest preoperative Ppa of those who showed improved or normalised haemodynamics postoperatively.

In conclusion, it has been shown that iloprost is a valuable alternative for the successful bridging to orthotopic liver transplantation of patients with severe portopulmonary hypertension. Regular echocardiographic screening of orthotopic livertransplantation candidates on the waiting list is mandatory, since portopulmonary hypertension may develop at any time.

Acknowledgments

The candid feedback provided to the authors by M.J. Krowka (Division of Pulmonary and Critical Care, The Mayo Clinic, Rochester, MN, USA) during the preparation of this manuscript is gratefully acknowledged.

  • Received December 2, 2003.
  • Accepted April 8, 2004.
  • © ERS Journals Ltd

References

  1. ↵
    Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153–1166.
    OpenUrlAbstract
  2. ↵
    Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension. Curr Treat Options Cardiovasc Med 2002;4:267–273.
  3. ↵
    Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 2003;133:163–169.
    OpenUrlPubMed
  4. ↵
    Krowka MJ, Porayko MK, Plevak DJ, et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 1997;72:44–53.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533–1544.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in livertransplant candidates. Liver Transpl Surg 1997;3:494–500.
    OpenUrlCrossRefPubMed
  7. ↵
    Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996;71:543–551.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 2002;8:382–388.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991;17:492–498.
    OpenUrlPubMedWeb of Science
  10. ↵
    Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443–450.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Plotkin JS, Kuo PC, Rubin LJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998;65:457–459.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641–648.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Ramsay MA, Spikes C, East CA, et al. The perioperative management of portopulmonary hypertension with nitricoxide and epoprostenol. Anesthesiology 1999;90:299–301.
    OpenUrlPubMedWeb of Science
  14. ↵
    Tan HP, Markowitz JS, Montgomery RA, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl 2001;7:745–749.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Mair P, Kaehler CH, Pomaroli A, Schwarz B, Vogel W, Margreiter R. Orthotopic liver transplantation in a patient with severe portopulmonary hypertension. Acta Anaesthesiol Scand 2001;45:513–518.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Kuo PC, Plotkin JS, Gaine S, et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999;67:1087–1093.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296–301.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997;63:604–606.
    OpenUrlPubMedWeb of Science
  19. ↵
    Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986;30:61–68.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998;79:175–179.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999;5:362–365.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Murata K, Shimizu A, Takase K, Nakano T, Tameda Y. Asymptomatic primary pulmonary hypertension associated with liver cirrhosis. J Gastroenterol 1997;32:102–104.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Yang YY, Lin HC, Lee WC, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001;36:181–186.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003;37:401–409.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453–458.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest 2003;123:562–576.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    De Wolf AM, Scott VL, Gasior T, Kang Y. Pulmonary hypertension and liver transplantation. Anesthesiology 1993;78:213–214.
    OpenUrlPubMed
  28. Koneru B, Ahmed S, Weisse AB, Grant GP, McKim KA. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation 1994;58:1133–1135.
    OpenUrlPubMedWeb of Science
  29. Losay J, Piot D, Bougaran J, et al. Early liver transplantation is crucial in children with liver disease and pulmonary artery hypertension. J Hepatol 1998;28:337–342.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Schott R, Chaouat A, Launoy A, Pottecher T, Weitzenblum E. Improvement of pulmonary hypertension after liver transplantation. Chest 1999;115:1748–1749.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    Levy MT, Torzillo P, Bookallil M, Sheil AG, McCaughan GW. Case report: delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. J Gastroenterol Hepatol 1996;11:734–737.
    OpenUrlPubMedWeb of Science
  32. ↵
    Mandell MS, Duke J. Nitric oxide reduces pulmonary hypertension during hepatic transplantation. Anesthesiology 1994;81:1538–1542.
    OpenUrlPubMedWeb of Science
  33. ↵
    Prager MC, Cauldwell CA, Ascher NL, Roberts JP, Wolfe CL. Pulmonary hypertension associated with liver disease is not reversible after liver transplantation. Anesthesiology 1992;77:375–378.
    OpenUrlPubMedWeb of Science
  34. ↵
    Rafanan AL, Maurer J, Mehta AC, Schilz R. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000;118:1497–1500.
    OpenUrlCrossRefPubMed
  35. ↵
    Kett DH, Acosta RC, Campos MA, Rodriguez MJ, Quartin AA, Schein RM. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl 2001;7:645–648.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    Koneru B, Fisher A, Wilson DJ, Klein KM, de la Torre AN, Seguel J. De novo diagnosis of portopulmonary hypertension following liver transplantation. Am J Transplant 2002;2:883–886.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 24 Issue 4 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension
S. Minder, M. Fischler, B. Muellhaupt, M.P. Zalunardo, R. Jenni, P-A. Clavien, R. Speich
European Respiratory Journal Oct 2004, 24 (4) 703-707; DOI: 10.1183/09031936.04.00133203

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension
S. Minder, M. Fischler, B. Muellhaupt, M.P. Zalunardo, R. Jenni, P-A. Clavien, R. Speich
European Respiratory Journal Oct 2004, 24 (4) 703-707; DOI: 10.1183/09031936.04.00133203
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Case report
    • Discussion
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Endobronchial pseudo-tumour caused by herpes simplex
  • Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease
  • Metabisulphite-induced occupational asthma in a radiographer
Show more Case Studies

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society